Bioprinting 101 – Part 17, Stem Cells
Stem cells have been an interesting topic within the medical field for ages. There lies a certain polarizing feel when one talks about the use of stem cells in general. This is the result of different societal values when associated to stem cell usage. We are going to address in particular, stem cells as a whole and what they are. We will also delve deeply into the field of bioprinting and how it is leveraging stem cells for the present and future of this field.
Stem cells are cells with the potential to develop into many different types of cells in the body. They serve as a repair system for the body. There are two main types of stem cells: embryonic stem cells and mesenchymal stem cells. Embryonic stem cells are pluripotent. This means they are able to differentiate into all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm. This means they can develop into each of the more than 200 cell types of the adult body as long as they are specified to do so. Mesenchymal stem cells are characterized morphologically by a small cell body with a few cell processes that are long and thin. These type of stem cells are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue).The cell body contains a large, round nucleus with a prominent nucleolus, which is surrounded by finely dispersed chromatin particles, giving the nucleus a clear appearance. The remainder of the cell body contains a small amount of Golgi apparatus, rough endoplasmic reticulum, mitochondria and polyribosomes. The cells, which are long and thin, are widely dispersed and the adjacent extracellular matrix is populated by a few reticular fibrils or fibers.
Stem cells are amazing in terms of the ability they provide medical professionals to create cells for different uses within the body. For example, one can take a stem cell and convert it to skin cells and then induce differentiation. This allows for the stem cell to progress to a larger scale such as a tissue for example. The differentiation process of a stem cell is the key to building new cells for different uses within the body. This is why stem cells are often cited in different areas as well in terms of medical solutions. However, the entire potential of stem cells can be harnessed only upon the resolution of associated issues and hurdles that fall in the way. Some of the key issues that limit the further exploration of stem cells in clinical trials include: the exploration of stem cells in clinical trials include safety concerns, formations of teratomas, transplantation issues and autoimmune response, and also ethical dilemmas. Teratomas are a type of germ cell tumor that may contain several different types of tissue, such as hair, muscle, and bone. Teratomas are of a huge concern for stem cell usage due to the ability for stem cells to differentiate. Differentiation refers to how cells can change into new cell types. Without proper control of the differentiation process, teratomas can form quickly, and this may lead to cancerous growth within the body. The strength of differentiation is also a weakness for usage within the clinical setting for stem cells and bioprinting in particular. Stem cells typically are used within syringe pump extrusion based bioprinting technology.
Extrusion based Stem Cell Bioprinting
Stem cells are still an interesting topic in the medical field. It will be intriguing to understand more of the mechanisms that lead to better control of stem cells. We are still learning and researching these methods. Ideally, we will try to talk to individuals who are focused on stem cell research and bioprinting applications in featured interviews soon.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
Print Services
You May Also Like
RAPID 2025: Stratasys & trinckle Announce Strategic Software Partnership
News continues to flood in from last week’s RAPID+TCT 2025, including a new partnership between AM market leader Stratasys and Berlin-based software company trinckle. By automating important steps in fixture...
RAPID TCT 2025: Spring in the Paris of the Midwest
I’m going to go out on a limb here and say that whomever coined the phrase Detroit: Paris of the Midwest, had not spent a lot of time in Paris...
3D Printing Financials: 3D Systems Looks to Bounce Back in 2025
After a challenging year for the industry, 3D Systems (NYSE: DDD) ended 2024 with results pointing to a reset, laying the groundwork for future profitability. The company didn’t post strong...
Printing Money Episode 27: Q4 2024 Public 3D Printing Earnings Review with Troy Jensen, Cantor Fitzgerald
Q2 2025 has already begun, but public markets reporting has only just finished with Q4 2024. To tie a bow on Q4 2024, we are thankful to have Troy Jensen...